Novartis upset over US patent legal setback

The multinational rose up the night of the reversal by an appeal court in the United States of previous court decisions granting prolonged protection to Gilenya against generic competition.

The Novartis action limited the damage Wednesday morning to the Swiss Stock Exchange. The multinational rose up the night of the reversal by an appeal court in the United States of previous court decisions granting prolonged protection to Gilenya against generic competition. The Rhine giant has already announced its intention to appeal against this verdict.

At 10:10 a.m., registered Novartis fell 0.65% to 78.33 francs, but remained well positioned in an SMI down 0.71%.

Vontobel recalls that Novartis has enjoyed – since 2018 and to everyone’s surprise at the time – an extension of protection in the land of Uncle Sam for this aging treatment against multiple sclerosis. The pharmaceutical giant has since reached agreements with several generic producers around a launch date for their own versions of Gilenya, without ever having delivered the timetable in question.

Stefan Schneider, an analyst with the Zurich management bank, had so far anticipated the arrival of this new competition by 2024, but no longer excludes a surge even before the end of the current financial year.

His colleague at the Zurich Cantonal Bank (ZKB), Laurent Flamme, recalls that generic competition is already eating away at Gilenya’s revenue outside the United States. However, the expert doubts a significant impact on the consensus of an introduction of copies across the Atlantic from 2023.

Leave a Comment